NASDAQ: DHCDiversified Healthcare Trust Stock
$6.94-0.05 (-0.72%)
Updated Apr 7, 2026
DHC Price
$6.94
Fair Value Price
-$5.98
Market Cap
$1.68B
52 Week Low
$2.00
52 Week High
$7.66
P/E
-5.83x
P/B
1.01x
P/S
0.76x
PEG
N/A
Dividend Yield
0.58%
Revenue
$1.54B
Earnings
-$285.89M
Gross Margin
18.1%
Operating Margin
-5.18%
Profit Margin
-18.6%
Debt to Equity
1.62
Operating Cash Flow
-$20M
Beta
1.28
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
DHC Overview
DHC is a real estate investment trust, or REIT, that owns medical office and life science properties, senior living communities and wellness centers throughout the United States. DHC is managed by the operating subsidiary of The RMR Group Inc., an alternative asset management company that is headquartered in Newton, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DHC's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Healthcare Facility REIT
Industry Rating
D
DHC
Ranked#7 of 17
Ranked#7 of 17
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $12.82 | B | |
| $16.36 | B | |
| $45.44 | C |
Be the first to know about important DHC news, forecast changes, insider trades & much more!
DHC News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DHC scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DHC ($6.94) is overvalued by 216.09% relative to our estimate of its Fair Value price of -$5.98 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
DHC ($6.94) is not significantly undervalued (216.09%) relative to our estimate of its Fair Value price of -$5.98 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DHC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more DHC due diligence checks available for Premium users.
Valuation
DHC fair value
Fair Value of DHC stock based on Discounted Cash Flow (DCF)
Price
$6.94
Fair Value
-$5.98
Undervalued by
216.09%
DHC ($6.94) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DHC ($6.94) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DHC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DHC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.83x
Industry
119.96x
Market
29.87x
DHC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.01x
Industry
2.65x
DHC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DHC's financial health
Profit margin
Revenue
$379.6M
Net Income
-$21.2M
Profit Margin
-5.6%
DHC's Earnings (EBIT) of -$79.65M... subscribe to Premium to read more.
Interest Coverage Financials
DHC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$4.4B
Liabilities
$2.7B
Debt to equity
1.62
DHC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
DHC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$20.1M
Investing
$207.4M
Financing
-$275.1M
DHC's operating cash flow (-$19.62M)... subscribe to Premium to read more.
Debt Coverage Financials
DHC vs Healthcare Facility REIT Stocks
Diversified Healthcare Trust Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.